Evidence map›Paper›PMID 36910511›Full record

ArticleAccess microbiology2023

Investigating

Renee M Fleeman, Michelle Mikesh, Bryan W Davies

Open access · goldAbstract read
In one paragraph

Article in Access microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. How to study biofilms: technological advancements in clinical biofilm research.Frontiers in cellular and infection microbiology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Renee M FleemanDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA.ORCID https://orcid.org/0000-0001-7103-461X
Michelle MikeshCenter for Biomedical Research Support, The University of Texas at Austin, Austin, TX 78712, USA.
Bryan W DaviesDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA.ORCID https://orcid.org/0000-0002-2046-0341
The University of Texas at Austin · USUniversity of Central Florida · US

Funding

Investigating nanobodies to target multidrug resistant bacterial pathogensR01AI148419 · NIAID · UNIVERSITY OF TEXAS AT AUSTIN · PI DAVIES, BRYAN WILLIAM · 2020 to 2023
$2.8M
A High-Throughput Molecular Platform for Antimicrobial Discovery and StudyR01AI125337 · NIAID · UNIVERSITY OF TEXAS AT AUSTIN · PI DAVIES, BRYAN WILLIAM · 2016 to 2020
$2.0M
Investigation of capsule interactions that promote antimicrobial peptide activityR21AI159203 · NIAID · UNIVERSITY OF TEXAS AT AUSTIN · PI DAVIES, BRYAN WILLIAM · 2021 to 2022
$429k
Refining our understanding of antimicrobial peptide mediated disruption of the Klebsiella pneumoniae capsuleK99AI163295 · NIAID · UNIVERSITY OF TEXAS AT AUSTIN · PI FLEEMAN, RENEE · 2021 to 2022
$176k
NIAID NIH HHS K99 AI163295NIAID NIH HHS L70 AI171976NIAID NIH HHS R01 AI125337NIAID NIH HHS R01 AI148419NIAID NIH HHS R21 AI159203
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

biofilmKlebsiella pneumoniaescanning electron microscopy

Identifiers

PMID36910511
PMCPMC9996182
OpenAlexW4319079614

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.